natgillin/translations-raw huggingface dataset:
and R2 are, independently of one another, hydrogen or C1-C4 alkyl and n is an integer from 5 to 100, and (ii) at least one propylene glycol fatty acid monoester or mixture of propylene glycol fatty acid mono- and diester, wherein the dosage form comprises, relative to the weight of the melt-processed mixture, from about 0.5 to 40 % by weight of said active ingredient, 40 to 99 % by weight of said pharmaceutically acceptable homopolymer or copolymer of N-vinylpyrrolidone, 0.5 to 20 % by weight of said solubilizing composition, and 0 to 15 % by weight of additives. 
i R2 su, neovisno jedan o drugome, hidrogen ili C1-C4 alkil i n je cijeli broj od 5 do 100, i (ii) barem jedan propilen glikol monoester masne kiseline ili smjesu propilen glikol mono- ili diester masne kiseline, naznačen time da doza sadrži, u odnosu na masu smjese taline, od otprilike 0,5 do 40 % mase aktivnog sastojka, 40 do 90 % mase farmaceutski prihvatljivog homopolimera ili kopolimera N-vinilpirolidona, 0,5 do 20 % mase otapajuće smjese, i 0 do 15 % mase aditiva.
The dosage form of claim1, wherein the tocopheryl compound is alpha tocopheryl polyethylene glycol succinate. 
Doza temeljem zahtjeva 1, naznačena time da je tokoferol sastojak alfa tokoferol polietilen glikol sukcinat.
The dosage form of claims 1 or 2, wherein the propylene glycol fatty acid monoester is propylene glycol monolaurate. 
Doza temeljem zahtjeva 1 ili 2, naznačena time da je propilen glikol monoester masne kiseline propilen glikol monolaurat.
The dosage form of any one of the preceding claims, wherein the weight ratio of tocopheryl compound and propylene glycol fatty acid ester is in the range of from 9:1 to 1:9. 
Doza temeljem bilo kojeg od prethodnih zahtjeva, naznačena time da je omjer mase tokoferol sastojka i propilen glikol estera masne kiseline između 9:1 i 1:9.
The dosage form of any one of the preceding claims, wherein the active ingredient is an HIV protease inhibitor or a combination of HIV protease inhibitors. 
Doza temeljem bilo kojeg od prethodnih zahtjeva, naznačena time da je aktivni sastojak inhibitor proteaze HIV-a ili kombinacija inhibitora proteaze HIV-a.
The method of claim 10, wherein the melt is shaped into a film or a foam before being allowed to solidify. 
Postupak temeljem zahtjeva 10, naznačen time da je talina u obliku filma ili pjene prije nego se pusti da očvrsne.
X is selected from the group consisting of O, S, NH and N-C1-6-alkyl; 
X je odabran iz skupine koju čine O, S, NH i N-C1-6-alkil;
and R10 together with the nitrogen atom connecting them form a 3 to 10 membered heterocycloaliphatic residue, which may be unsubstituted or mono- or polysubstituted; 
i R10 zajedno s atomom dušika koji ih spaja tvore 3 do 10 člani heterocikloalifatski ostatak, koji može biti nesupstituiran ili mono- ili polisupstituiran;
Compounds according to one or more of the preceding claims, characterized in that R4 represents CHF2 or CF3. 
Spojevi prema jednom ili više od prethodnih zahtjeva, naznačeni time da R4 predstavlja CHF2 ili CF3.
Compounds according to one or more of the preceding claims, characterized in that R5 is selected from the group consisting of H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, cyclopropyl, methoxy, ethoxy, methylsulfonyl, 2-oxetyl, 3-oxetyl, 2-tetrahydrofuranyl and 3-tetrahydrofuranyl. 
Spojevi prema jednom ili više od prethodnih zahtjeva, naznačeni time da R5 je odabran iz skupine koju čine H, metil, etil, n-propil, izo-propil, n-butil, sec-butil, izo-butil, tert-butil, ciklopropil, metoksi, etoksi, metilsulfonil, 2-oksetil, 3-oksetil, 2-tetrahidrofuranil i 3-tetrahidrofuranil.
and R12 together with the carbon atom connecting them form a C3-6 cycloaliphatic residue or a 3-7-membered heterocycloaliphatic residue, which contains 1 or 2 heteroatoms or heteroatom groups independently from one another selected from the group consisting of O, S, S(=O), S(=O)2, NH and N-C1-6-alkyl, wherein said C3-6- cycloaliphatic residue or 3-7-membered heterocycloaliphatic residue may be unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently from one another selected from the group consisting of F, Cl, CF3, OCF3, CN, C1-6-alkyl and O-C1-6-alkyl; 
i R12 zajedno s atomom ugljika ih povezuje tvore C3-6 cikloalifatski ostatak ili 3-7-člani heterocikloalifatski ostatak, koji sadrži 1 ili 2 heteroatoma ili skupina heteroatoma međusobno neovisno odabranih iz skupine koju čine O, S, S(=O), S(=O)2, NH i N-C1-6-alkil, pri čemu navedeni C3-6- cikloalifatski ostatak ili 3-7-člani heterocikloalifatski ostatak može biti nesupstituiran ili supstituiran s 1, 2, 3, 4 ili 5 supstituenata međusobno neovisno odabranih iz skupine koju čine F, Cl, CF3, OCF3, CN, C1-6-alkil i O-C1-6-alkil;
or and R10 together with the nitrogen atom connecting them form a 3-7-membered heterocycloaliphatic residue selected from the group consisting of wherein 
ili i R10 zajedno s atomom dušika koji ih povezuje tvore 3-7-člani heterocikloalifatski ostatak odabran iz skupine koju čine [image] [image] [image] pri čemu
Compounds according to one or more of the preceding claims, characterized in that n represents 1 and m represents 0; 
Spojevi prema jednom ili više od prethodnih zahtjeva, naznačeni time da n predstavlja 1 i m predstavlja 0;
and R12 together with the carbon atom connecting them form a C3-6 cycloaliphatic residue or a 3-7-membered heterocycloaliphatic residue, which contains 1 or 2 heteroatoms or heteroatom groups independently from one another selected from the group consisting of O, S, S(=O), S(=O)2, NH and N-C1-6-alkyl, wherein said C3-6-cycloaliphatic residue or 3-7-membered heterocycloaliphatic residue is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently from one another selected from the group consisting of F, CF3, OCF3 CN, C1-6-alkyl and O-C1-6-alkyl; 
i R12 zajedno s atomom ugljika ih povezuje tvore C3-6 cikloalifatski ostatak ili 3-7-člani heterocikloalifatski ostatak, koji sadrži 1 ili 2 heteroatoma ili skupina heteroatoma međusobno neovisno odabranih iz skupine koju čine O, S, S(=O), S(=O)2, NH i N-C1-6-alkil, pri čemu je navedeni C3-6-cikloalifatski ostatak ili 3-7-člani heterocikloalifatski ostatak nesupstituiran ili supstituiran s 1, 2, 3, 4 ili 5 supstituenata međusobno neovisno odabranih iz skupine koju čine F, CF3, OCF3 CN, C1-6-alkil i O-C1-6-alkil;
n is a number from zero to 4; 
n je broj od nula do 4;
is unsubstituted methyl, or is C2-4alkyl unsubstituted or substituted with hydroxy, methoxy, or halo; and m is 1 or 2; or is 
je nesupstituirani metil, ili je C2-4alkil nesupstituiran ili supstituiran s hidroksi, metoksi, ili halo; i m je 1 ili 2; ili je
a is one or two; 
a je jedan ili dva;
Ring A is an aromatic ring; 
prsten A je aromatski prsten;
and R10 are independently selected from hydrogen and C1-6alkyl; 
i R10 su neovisno odabrani od vodika i C1-6alkila;
wherein alkyl is unsubstituted or substituted with amino, hydroxyl, or halo; 
pri čemu alkil je nesupstituiran ili supstituiran s amino, hidroksilom, ili halo;
is selected from hydrogen and C1-6 alkyl; and 
je odabran od vodika i C1-6 alkila; i
and R2 are independently selected from hydrogen, halo, C1-6 alkyl, and C1-6 haloalkyl; 
i R2 su neovisno odabrani iz niza koji čine vodik, halo, C1-6alkil, i C1-6haloalkil;
The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13, for use in the treatment or prevention of a proliferation disorder, cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease. 
Spoj prema bilo kojem od zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema zahtjevu 13, naznačen time da je za uporabu za liječenje ili sprječavanje poremećaja proliferacije, raka, tumora, upalne bolesti, autoimune bolesti, psorijaze, bolesti suhog oka ili imunološki srodne bolesti.
The compound or pharmaceutical composition for use of claim 14, wherein the proliferation disorder is selected from the group consisting of sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non- small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head and neck cancers, and pancreatic cancer. 
Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 14, naznačen time daje poremećaj proliferacije odabran iz skupine koju čine sarkom, epidermoidni rak, fibrosarkom, karcinom vrata maternice, karcinom želuca, rak kože, leukemija, limfom, karcinom pluća, rak pluća ne-malih stanica, rak debelog crijeva, rak središnjeg živčanog sustava, melanom, rak jajnika, rak bubrega, rak prostate, rak dojke, rak jetre, karcinom glave i vrata, te rak gušterače.
A combination of a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and a second prophylactic or therapeutic agent for use in the treatment or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye, or an immunologically related disease in a subject. 
Kombinacija spoja prema bilo kojem od zahtjeva 1 do 12, ili njegove farmaceutski prihvatljive soli, i drugog profilaktičkog ili terapijskog sredstva naznačena time daje za uporabu za liječenje ili sprječavanje poremećaja proliferacije, raka, tumora, upalne bolesti, autoimune bolesti, psorijaze, bolesti suhog oka ili imunološki srodne bolesti kod subjekta.
connection (51) by overlaying said layer of rigid material (11) on said layer of flexible support material (12), in example by glue; 
spajanje (51), primjerice ljepilom, stavljajući navedeni sloj krutog materijala (11) na navedeni sloj savitljivog potpornog materijala (12);
design (52) of a texture in vector graphics (14) defining a structure of lines, and download it into a control system of an industrial device able to generate and focus a high power laser beam, called laser device; 
određivanje (52) teksture u vektorskoj grafici (14) određujući strukturu linija, i pohranjujući to u upravljački sustav industrijskog uređaja nazvanog laserski uređaj, koji je sposoban da generira i usmjeri lasersku zraku velike snage;
said new material (18a), (18b), (18c), is submitted to a further step of gluing and/or sewing in parts of tissue, in such a way to be suitable in tailoring to create clothes, tents, accessories, etc. 
navedeni novi materijal (18a), (18b), (18c) se podvrgava daljnjem stupnju ljepljenja i/ili ušivanja u dijelove tkanine, na takav način da bude prikladan za krojenje u izradi odjeće, zavjesa, dodatnog pribora i t.d.
Process (50) able to produce said multilayer flexible element (10) according to previous claim 1, said process (50) being characterized by the following additional step: 
Postupak (50) za proizvodnju navedenog višeslojnog savitljivog elementa (10) prema prethodnom patentnom zahtjevu 1, a navedeni je postupak (50) naznačen time, da ima sljedeći dodatni stupanj:
the above-mentioned new material (18a), (18b), (18c), is treated with hardeners resins fixing its shapes, in such a way to make it rigid and applicable for example in furniture or vehicle industries. 
gorenavedeni novi materijal (18a), (18b), (18c) se obrađuje otvrdnjavajućom smolom koja fiksira njegove oblike, na takav način da ga se učini krutim i primjenjivim, u primjerice, industriji namještaja ili vozila.
Multilayer flexible element (10), according to previous claim 3, characterized in that: 
Višeslojni savitljivi element (10) prema prethodnom patentnom zahtjevu 3, naznačen time, da
the flexible support (12) has the same size of the rigid material (11) which will be glued; 
savitljiva potpora (12) ima istu dimenziju krutog materijala (11) na koji će se lijepiti;
the flexible support (12) has a uniform surface, in such a way to allow adequate gluing. 
savitljiva potpora (12) ima ujednačenu površinu, tako da je moguće svrsishodno ljepljenje.
Multilayer flexible element (10), according to one or more of previous claims 3 or, characterized in that: 
Višeslojni savitljivi element (10) prema jednom ili više od prethodnih patentnih zahtjeva 3 ili 4, naznačen time, da:
said glue (13), to be used to connect said layer of rigid material (11) to said flexible support material (12), has chemical-physical characteristics suitable to maintain high elasticity, water resistance and temperature changes resistance after drying, in such a way to glue the two sheets of material definitely. 
navedeno ljepilo (13) koje treba primijeniti da se spoji navedeni sloj od krutog materijala (11) s navedenim potpornim materijalom (12), ima kemijsko-fizikalne osobine prikladne da održavaju visoku elastičnost, vodootpornost i otpornost na temperaturne promjene nakon sušenja, tako da se listovi dva materijala zalijepe u konačnom obliku.
Multilayer flexible element (10), according to one or more of previous claims from 3 to 8, characterized in that: 
Višeslojni savitljivi element (10) prema jednom ili više od prethodnih patentnih zahtjeva od 3 do 8, naznačen time, da:
the laser device (16) is calibrated so that power, velocity and degree of definition affect only the thickness of the rigid material (11), leaving unchanged the layer of adhesive (13) and the underlying flexible support (12). 
je laserski uređaj (16) kalibriran tako, da snaga, brzina i stupanj definicije djeluje samo u debljini krutog materijala (11), ostavljajući neizmijenjenim sloj ljepila (13) i savitljive potpore (12) ispod njega.
represents substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, wherein heterocyclyl is a stable 3-to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; 
predstavlja supstituirani ili nesupstituirani, aromatski ili nearomatski heterociklil, gdje je heterociklil stabilni 3- do 15-eročlani prstenasti radikal, koji se sastoji od atoma ugljika i od jednog do pet heteroatoma, koje se bira iz skupine koju čine dušik, kisik, te sumpor;
substituted or unsubstituted aryl, wherein aryl is a group containing from 1 to 3 separated or fused rings and from 6 to 18 carbon ring atoms; or substituted or unsubstituted cycloalkyl, wherein cycloalkyl is a stable 3-to 10-membered monocyclic or bicyclic radical which is saturated or partially saturated; 
supstituirani ili nesupstituirani aril, gdje je aril skupina koja sadrži od 1 do 3 odvojenih ili kondenziranih prstena i od 6 do 18 atoma ugljika u prstenu; ili supstituirani ili nesupstituirani cikloalkil, gdje je cikloalkil stabilni 3- do 10-eročlani monociklički ili biciklički radikal, koji je zasićen ili djelomično zasićen;
wherein substitution in any of the substituted groups defined for R1, R2 and R3 is substitution at one or more available positions by one or more groups selected from halogen; cyano; hydroxyl; nitro; azido; acyl; carboxamido; alkyl groups having 1 to 12 carbon atoms; alkenyl groups having one or more unsaturated linkages and from 2 to 12 carbon atoms; alkynyl groups having one or more unsaturated linkages and from 2 to 12 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to 12 carbon atoms; aryloxy; alkylthio groups having one or more thioether linkages and from 1 to 12 carbon atoms; alkylsulfinyl groups having one or more sulfinyl linkages and from 1 to 12 carbon atoms; alkylsulfonyl groups having one or more sulfonyl linkages and from 1 to 12 carbon atoms; aminoalkyl groups having one or more N atoms and from 1 to 12 carbon atoms; carbocylic aryl having 6 or more carbons; 
gdje je supstitucija u bilo kojoj od supstituiranih skupina definiranih za R1, R2 i R3 supstitucija na jednom ili više dostupnih položaja s jednom ili više skupina, koje se bira između halogena; cijano; hidroksila; nitro; azido; acila; karboksamido; alkilnih skupina s 1 do 12 atoma ugljika; alkenilnih skupina s jednom ili više nezasićenih veza i s 2 do 12 atoma ugljika; alkinilnih skupina s jednom ili više nezasićenih veza i s 2 do 12 atoma ugljika; alkoksi skupina s jednom ili više kisikovih spojnica i s 1 do 12 atoma ugljika; ariloksi; alkiltio skupina s jednom ili više tioeterskih spojnica i s 1 do 12 atoma ugljika; alkilsulfinilnih skupina s jednom ili više sulfinilnih spojnica i s 1 do 12 atoma ugljika; alkilsulfonilnih skupina s jednom ili više sulfonilnih spojnica i s 1 do 12 atoma ugljika; aminoalkilnih skupina s jednim ili više N atoma i s 1 do 12 atoma ugljika; karbocikličkog arila s 6 ili više ugljika;
and R5 together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, non-aromatic heterocyclyl, wherein heterocyclyl is a stable 5-or 6-membered ring radical which consists of carbon atoms and one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; 
i R5, zajedno s atomom dušika na kojeg su vezani, tvore supstituirani ili nesupstituirani, nearomatski heterociklil, gdje je heterociklil stabilni 5- ili 6-eročlani prstenasti radikal, koji se sastoji od atoma ugljika i jednog ili više heteroatoma, koje se bira iz skupine koju čine dušik, kisik, te sumpor;
wherein substitution in the substituted heterocyclyl which R4 and R5 together form is substitution at one or more available positions by one or more groups selected from halogen; cyano; hydroxyl; nitro; azido; acyl; carboxamido; alkyl groups having 1 to 12 carbon atoms; alkenyl groups having one or more unsaturated linkages and from 2 to 12 carbon atoms; alkynyl groups having one or more unsaturated linkages and from 2 to 12 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to 12 carbon atoms; alkylthio groups having one or more thioether linkages and from 1 to 12 carbon atoms; alkylsulfinyl groups having one or more sulfinyl linkages and from 1 to 12 carbon atoms; alkylsulfonyl groups having one or more sulfonyl linkages and from 1 to 12 carbon atoms; aminoalkyl groups having one or more N atoms and from 1 to 12 carbon atoms; 
gdje je supstitucija u supstituiranom heterociklilu kojeg zajedno tvore R4 i R5 supstitucija na jednom ili više dostupnih položaja s jednom ili više skupina, koje se bira između halogena; cijano; hidroksila; nitro; azido; acila; karboksamido; alkilnih skupina s 1 do 12 atoma ugljika; alkenilnih skupina s jednom ili više nezasićenih veza i s 2 do 12 atoma ugljika; alkinilnih skupina s jednom ili više nezasićenih veza i s 2 do 12 atoma ugljika; alkoksi skupina s jednom ili više kisikovih spojnica i s 1 do 12 atoma ugljika; alkiltio skupina s jednom ili više tioeterskih spojnica i s 1 do 12 atoma ugljika; alkilsulfinilnih skupina s jednom ili više sulfinilnih spojnica i s 1 do 12 atoma ugljika; alkilsulfonilnih skupina s jednom ili više sulfonilnih spojnica i s 1 do 12 atoma ugljika; aminoalkilnih skupina s jednim ili više N atoma i s 1 do 12 atoma ugljika;
m is selected from 1 and 2; 
m se bira između 1 i 2;
or a pharmaceutically acceptable salt, enantiomer, diastereoisomer or solvate thereof. 
ili njegova farmaceutski prihvatljiva sol, enantiomer, dijastereoizomer ili solvat.
The compound according to claim 1, wherein R1 is selected from substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted thiophene, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzofuran, substituted or unsubstituted pyridine and substituted or unsubstituted quinoline; wherein substitution in any of the defined substituted groups is as defined in claim 1. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 se bira između supstituiranog ili nesupstituiranog ciklopentila, supstituiranog ili nesupstituiranog cikloheksila, supstituiranog ili nesupstituiranog fenial, supstituiranog ili nesupstituiranog naftila, supstituiranog ili nesupstituiranog tiofena, supstituiranog ili nesupstituiranog benzotiofena, supstituiranog ili nesupstituiranog benzofurana, supstituiranog ili nesupstituiranog piridina i supstituiranog ili nesupstituiranog kinolina; gdje je supstitucija bilo kojom od definiranih supstituiranih skupine definirana kao u patentnom zahtjevu 1.
The compound according to any of the preceding claims, wherein R4 and R5 form together a morpholine-4-yl group, a piperidine group, pyrrolidine group or a piperazine-4-yl group. 
Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što R4 i R5 zajedno tvore morfolin-4-ilnu skupinu, piperidinsku skupinu, pirolidinsku skupina ili piperazin-4-ilnu skupinu.
Compound for use according to claim 10, wherein the medicament is for the treatment and/or prophylaxis of a sigma receptor-mediated disease or condition, wherein the disease or condition comprises diarrhea; lipoprotein disorders; migraine; obesity; elevated triglyceride levels; chylomicronemia; dysbetalipoproteinemia; hyperlipoproteinemia; hyperlipidemia; mixed hyperlipidemia; hypercholesterolemia; hypertriglyceridemia; sporadic hypertriglyceridemia; inherited hypertriglyceridemia; dysbetalipoproteinemia; arthritis; hypertension; arrhythmia; ulcer; learning, memory and attention deficits; cognition disorders; neurodegenerative diseases; demyelinating diseases; addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine; tardive dyskinesia; ischemic stroke; epilepsy; stroke; stress; cancer; psychotic conditions, in particular depression, anxiety or schizophrenia; inflammation; and autoimmune diseases. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je medikament namijenjen liječenju i/ili sprječavanju bolesti ili stanja uzrokovanog aktivnošću sigma receptora, gdje bolest ili stanje uključuje proljev; lipoproteinske poremećaje; migrenu; pretilost; povišene razin triglicerida; hilomikronemiju; disbetalipoproteinemiju; hiperlipoproteinemiju; hiperlipidemiju; miješanu hiperlipidemiju; hiperkolesterolemiju; hipertrigliceridemiju; povremenu hipertrigliceridemiju; nasljednu hipertrigliceridemiju; disbetalipoproteinemiju; artritis; hipertenziju; aritmiju; vrijed; poremećaje učenja, pamćenja i pažnje; poremećaje kognitivnih funkcija; neurodegenerativne bolesti; demijelinirajuće bolesti; ovisnost o narkotičniima i kemijskim tvarima, uključujući kokain, amfetamin, etanol i nikotin; tardivnu diskineziju; ishemični inzult; epilepsiju; inzult; stres; rak; psihotična stanja, osobito depreziju, anksioznost ili shizofreniju; upala; te autoimune bolesti.
Compound for use according to claim 10, wherein the medicament is for the treatment and/or prophylaxis of a sigma receptor-mediated disease or condition, wherein the disease or condition comprises pain, preferably neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je medikament namijenjen liječenju i/ili sprječavanju bolesti ili stanja uzrokovanog aktivnošću sigma receptora, gdje bolest ili stanje uključuje bol, po mogućnosti neuropatsku bol, upalnu bol ili druga bolna stanja, koja uključuju alodiniju i/ili hiperalgeziju.
The dimer of claim 6, wherein the protein has the sequence selected from the group consisting of SEQ ID NO: 60, 62, 64, 87, 88, 91, 93, 95, and 97. 
Izolirani protein prema zahtjevu 6, naznačen time, što protein ima sekvencu odabranu iz grupe koja se sastoji od SEQ ID NO: 60, 62, 64, 87, 88, 91, 93, 95 i 97.